EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Refining a preclinical model of viral myocarditis in accordance with biotech standards

Jonas Stewen, Julia Riedesel, Juliane Stein, Brandon H Greene, Svenja Rohde, Sonja Suess, Bjoern Keiner, Priya Panjwani, Padmapriya Ponnuswamy, Juan E Camacho Londoño iD

Animal Models and Experimental Medicine · 2026

DOI: 10.1002/ame2.70263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Animal Models and Experimental Medicine, 2026. Verfasst von Jonas Stewen und 9 weiteren Autor:innen. Beteiligte Einrichtung: CSL Innovation GmbH, Marburg, Germany. Hauptthemen laut MEDLINE: Myocarditis, Disease Models, Animal, Coxsackievirus Infections. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CSL Innovation GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Viral myocarditis is a clinically relevant inflammatory heart disease that can progress to dilated cardiomyopathy and heart failure. However, preclinical models often suffer from limited translational relevance and high animal burden.

Methods

This study aimed to refine a murine model of Coxsackievirus B3 (CVB3)‐induced myocarditis by integrating dietary and imaging innovations to improve animal welfare, data quality, and clinical applicability. BALB/cJ mice were infected with heart‐passaged CVB3 and monitored for up to 56 days. A hydrolyzed amino acid diet was introduced to mitigate CVB3‐induced pancreatitis and associated weight loss. Cardiac function was assessed using 1D, 2D, and 4D echocardiography, including speckle‐tracking strain analysis.

Results

The refined diet significantly reduced animal health burden, reduced weight loss, and stabilized blood glucose, during development of cardiac inflammation and fibrosis. 4D echocardiography provided a highly sensitive and reproducible detection of systolic dysfunction, while strain analysis revealed early and regional myocardial impairment, closely mirroring clinical myocarditis phenotypes. Histopathological and AI‐based analyses confirmed dose‐ and time‐dependent inflammation and fibrosis, with peak inflammation at day 7 and persistent abnormalities through day 56.

Conclusions

In summary, this model offers a robust and ethically optimized platform for translational research and therapeutic development in inflammatory cardiomyopathies, aligned with the principles of the 3Rs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyocarditisDisease Models, AnimalCoxsackievirus InfectionsAnimalsEnterovirus B, HumanMice, Inbred BALB CMiceEchocardiographyMale

Stichwörter der Autor:innen

3Rsanimal welfarecoxsackiemousetranslation

Autor:innen und Institutionen

  • CSL Innovation GmbH, Marburg, Germany.

ORCID-Profile: Juan E Camacho Londoño

Förderung

  • CSL Innovation GmbH

Zitieren

APA

Stewen, J., Riedesel, J., Stein, J., Greene, B. H., Rohde, S., Suess, S., Keiner, B., Panjwani, P., Ponnuswamy, P., & Camacho Londoño, J. E. (2026). Refining a preclinical model of viral myocarditis in accordance with biotech standards. Animal Models and Experimental Medicine. https://doi.org/10.1002/ame2.70263

Vancouver

Stewen J, Riedesel J, Stein J, Greene BH, Rohde S, Suess S, et al. Refining a preclinical model of viral myocarditis in accordance with biotech standards. Animal Models and Experimental Medicine. 2026. doi:10.1002/ame2.70263

BibTeX
@article{Stewen2026,
  author = {Stewen, Jonas and Riedesel, Julia and Stein, Juliane and Greene, Brandon H and Rohde, Svenja and Suess, Sonja and Keiner, Bjoern and Panjwani, Priya and Ponnuswamy, Padmapriya and Camacho Londoño, Juan E},
  title = {Refining a preclinical model of viral myocarditis in accordance with biotech standards},
  journal = {Animal Models and Experimental Medicine},
  year = {2026},
  doi = {10.1002/ame2.70263}
}
Kostenlos starten →